A $499 annual membership is the latest expression of a 15-year bet: health startups need buyers, backers, and each other. StartUp Health is turning that belief into a business built around shared medical missions.
Catalonia can produce the science. Getting it into everyday care is another job. Biocat is building the connections, training and routes into the health system that make that journey possible.
A good health invention can spend years waiting for a buyer. Geneva’s Health Innovation Exchange brings ministries, founders and investors together to help promising solutions reach the people they were built for.
In northern Nigeria, FutureMap Foundation is linking digital training to employers, local problems, and a community clinic. Its most interesting experiment begins where the classroom ends.
From faster wound healing to diabetes classes that understand the dinner table, Health Innovation Network South London tackles the awkward distance between a promising idea and everyday care.
The Ottawa Hospital Foundation turned an intimidating capital project into a citywide invitation - and has raised $404 million toward a $500 million goal. Its playbook is less about gala glamour than a disciplined mix of giant anchor gifts, recurring donors, personal stories and proof of impact.
David Schummers is the co-founder and CEO of Apella Technology, a San Francisco-based ambient AI company transforming how hospitals run their operating rooms. Using computer vision and machine learning, Apella captures real-time surgical intelligence - automatically documenting up to 14 case events per procedure and feeding structured data back into EHR systems - reducing OR turnover times by 16% and increasing case volume by 10%. Before founding Apella in 2019, Schummers spent two decades in health technology, including a pivotal stint at Auris Health as its first commercial executive, where he helped engineer the company's $5.7 billion acquisition by Johnson & Johnson in 2019 - at the time the largest medical technology startup transaction in history. Apella raised an $80 million Series B in January 2026 led by HighlandX, bringing total funding to over $104 million.
Sach Jain is the Founder & CEO of Carrum Health, a San Francisco-based value-based care platform that connects self-insured employers with top-tier hospitals and surgical centers through bundled payment arrangements. Founded in 2014 after Jain's frustration with America's fee-for-service healthcare system, Carrum Health has raised $96M in total funding and now covers 90% of the US population through a network that includes Mayo Clinic, Cleveland Clinic, Johns Hopkins, and Stanford. With a background spanning IIT Delhi, University of Chicago Booth, investment banking at Bank of America Merrill Lynch, and healthcare consulting at Booz & Company, Jain built Carrum to solve a systemic problem: employers spending $20,000+ per employee annually on health benefits with up to a 10x pricing variation for identical procedures.
Rick Winningham is the CEO of Theravance Biopharma, a biopharmaceutical company focused on organ-selective medicines for serious diseases including COPD, rare neurological conditions, and inflammatory diseases. With over 40 years in the pharmaceutical industry - including 13 years as CEO of Innoviva and 15 years at Bristol-Myers Squibb - Winningham has built a career defined by transformative drug development, strategic company leadership, and a widely recognized commitment to mentoring the next generation of biopharma executives, particularly women in leadership. He was named the 2026 HBA Honorable Mentor by the Healthcare Businesswomen's Association.